Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B

Bicycle, Novartis Ink Oncology Deal Worth up to $1.7B

Source: 
BioSpace
snippet: 

Bicycle Therapeutics and Novartis announced Tuesday they have inked a deal worth up to $1.7 billion to discover and develop several targeted radioligand therapies in oncology.